OraSure Technologies (NASDAQ:OSUR) updated its FY 2019 earnings guidance on Tuesday. The company provided earnings per share guidance of $0.24-0.26 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $165-170 million, compared to the consensus revenue estimate of $172.81 million.OraSure Technologies also updated its FY19 guidance to $0.24-0.26 EPS.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of OraSure Technologies from a hold rating to a sell rating in a report on Tuesday, July 9th. Canaccord Genuity cut shares of OraSure Technologies from a buy rating to a hold rating and set a $10.00 target price on the stock. in a report on Thursday, May 9th. Finally, BidaskClub cut shares of OraSure Technologies from a hold rating to a sell rating in a report on Thursday, July 18th. Three investment analysts have rated the stock with a sell rating and one has given a hold rating to the company. OraSure Technologies has an average rating of Sell and an average target price of $10.00.
OSUR traded down $0.33 on Friday, reaching $7.53. The company had a trading volume of 869,500 shares, compared to its average volume of 648,462. OraSure Technologies has a fifty-two week low of $7.15 and a fifty-two week high of $17.11. The firm has a market cap of $485.86 million, a PE ratio of 15.06, a P/E/G ratio of 2.72 and a beta of 1.19. The firm’s fifty day simple moving average is $8.64. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.56 and a current ratio of 7.52.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.04. OraSure Technologies had a net margin of 11.83% and a return on equity of 7.86%. The business had revenue of $38.83 million for the quarter, compared to analyst estimates of $41.48 million. During the same quarter in the prior year, the business earned $0.07 EPS. OraSure Technologies’s quarterly revenue was down 11.0% on a year-over-year basis. Research analysts forecast that OraSure Technologies will post 0.25 earnings per share for the current fiscal year.
In related news, SVP Jack E. Jerrett purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average price of $8.55 per share, for a total transaction of $85,500.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.70% of the stock is currently owned by corporate insiders.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
See Also: Cash Flow Analysis in Stock Selection
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.